期刊
EBIOMEDICINE
卷 32, 期 -, 页码 119-124出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2018.05.019
关键词
Anti-CTLA-4; TP53; Melanoma; Biomarker; Tumor mutational
资金
- National Natural Science Foundation of China [81773285]
TP53 has been proved to be associatedwith cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastatic melanoma by analyzing the data from one public cohort consisting of 110 patients with metastatic melanoma. The sequencing, mRNA and survival data of 368 patients with skin melanoma from The Cancer Genome Atlas (TCGA) was used to explore the underlying mechanism. TP53 mutation was associated with significant poorer progression-free survival (HR, 2.25; 95% CI, 1.15-4.37; P = 0.014), poorer overall survival (HR, 2.05; 95% CI, 1.02-4.13; P = 0.040) and trend of poorer response (OR, 0.20; 95% CI, 0.02-1.62; P = 0.131). The correlations were significant in multivariate analysis including lactate dehydrogenase, tumor mutational burden and tumor stage (P < 0.05). In TCGA, no association was observed between TP53 mutation and survival (P = 0.55). The mRNA expression of FAS was lower in patientswith TP53 mutation than TP53wild-type. Our findings suggest that TP53mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade. (C) 2018 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据